AKERO THERAPEUTICS INC (AKRO)
US00973Y1082 - Common Stock
We assign a fundamental rating of 2 out of 10 to AKRO. AKRO was compared to 602 industry peers in the Biotechnology industry. The financial health of AKRO is average, but there are quite some concerns on its profitability. AKRO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year AKRO has reported negative net income.
In the past year AKRO has reported a negative cash flow from operations.
In the past 5 years AKRO always reported negative net income.
In the past 5 years AKRO always reported negative operating cash flow.
1.2 Ratios
AKRO has a Return On Assets of -18.83%. This is amongst the best in the industry. AKRO outperforms 82.78% of its industry peers.
Looking at the Return On Equity, with a value of -20.52%, AKRO belongs to the top of the industry, outperforming 84.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.83% | ||
| ROE | -20.52% | ||
| ROIC | N/A |
ROA(3y)-37.32%
ROA(5y)-50.03%
ROE(3y)-41.51%
ROE(5y)-53.69%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for AKRO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, AKRO has more shares outstanding
The number of shares outstanding for AKRO has been increased compared to 5 years ago.
The debt/assets ratio for AKRO is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 9.83 indicates that AKRO is not in any danger for bankruptcy at the moment.
The Altman-Z score of AKRO (9.83) is better than 89.80% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that AKRO is not too dependend on debt financing.
AKRO has a worse Debt to Equity ratio (0.04) than 61.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.83 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 20.28 indicates that AKRO has no problem at all paying its short term obligations.
The Current ratio of AKRO (20.28) is better than 94.48% of its industry peers.
A Quick Ratio of 20.28 indicates that AKRO has no problem at all paying its short term obligations.
The Quick ratio of AKRO (20.28) is better than 94.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 20.28 | ||
| Quick Ratio | 20.28 |
3. Growth
3.1 Past
AKRO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.06%, which is quite impressive.
EPS 1Y (TTM)30.06%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q22.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
The Earnings Per Share is expected to grow by 10.31% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.44%
EPS Next 2Y-11.12%
EPS Next 3Y-11.58%
EPS Next 5Y10.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
AKRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AKRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as AKRO's earnings are expected to decrease with -11.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.12%
EPS Next 3Y-11.58%
5. Dividend
5.1 Amount
No dividends for AKRO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AKERO THERAPEUTICS INC
NASDAQ:AKRO (11/30/2023, 5:47:15 PM)
After market: 16.461 -0.28 (-1.67%)16.74
+0.08 (+0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2023-11-13/bmo
Earnings (Next)03-15 2024-03-15/amc
Inst Owners108%
Inst Owner Change5.94%
Ins Owners8.37%
Ins Owner Change-0.51%
Market Cap930.74M
Analysts84
Price Target44.43 (165.41%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.08%
Min EPS beat(2)-2.18%
Max EPS beat(2)6.33%
EPS beat(4)3
Avg EPS beat(4)15.93%
Min EPS beat(4)-2.18%
Max EPS beat(4)39.8%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)-40.33%
PT rev (3m)-27.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.14%
EPS NY rev (1m)0%
EPS NY rev (3m)1.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.6 | ||
| P/tB | 1.6 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.35
EYN/A
EPS(NY)-3.61
Fwd EYN/A
FCF(TTM)-2.2
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS0
BVpS10.49
TBVpS10.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.83% | ||
| ROE | -20.52% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-37.32%
ROA(5y)-50.03%
ROE(3y)-41.51%
ROE(5y)-53.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 20.28 | ||
| Quick Ratio | 20.28 | ||
| Altman-Z | 9.83 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y (TTM)30.06%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q22.83%
EPS Next Y4.44%
EPS Next 2Y-11.12%
EPS Next 3Y-11.58%
EPS Next 5Y10.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.89%
EBIT Next 3Y-22.54%
EBIT Next 5Y18.23%
FCF growth 1Y-60.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.05%
OCF growth 3YN/A
OCF growth 5YN/A